rasagiline
Selected indexed studies
- Rasagiline. (Drugs Aging, 2005) [PMID:15663351]
- Rasagiline for the treatment of Parkinson's disease: an update. (Expert Opin Pharmacother, 2015) [PMID:26364897]
- Rasagiline in neurodegeneration. (Exp Neurol, 2008) [PMID:18571162]
_Worker-drafted node — pending editorial review._
Connections
rasagiline is a side effect of
Sources
- Rasagiline. (2005) pubmed
- Rasagiline for the treatment of Parkinson's disease: an update. (2015) pubmed
- Rasagiline in neurodegeneration. (2008) pubmed
- Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate α-synuclein cytotoxicity in disease-modifying therapy for Parkinson's disease. (2020) pubmed
- Efficacy of rasagiline monotherapy for early Parkinson disease: A systematic review and meta-analysis of randomized controlled trials. (2022) pubmed
- Rasagiline combined with levodopa therapy versus levodopa monotherapy for patients with Parkinson's disease: a systematic review. (2020) pubmed
- Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. (2010) pubmed
- Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease. (2014) pubmed
- Rasagiline Withdrawal Syndrome in Parkinson's Disease. (2022) pubmed
- Rasagiline in Parkinson's disease. (2011) pubmed